Beauty Launchpad

JANUARY 10, 2025

The need for support for beauty professionals in the Los Angeles area is urgent. Here's how you can request aid or donate to those impacted by the wildfires in Los Angeles.

52

52

West Lake Dermatology

JANUARY 10, 2025

The global demand for cosmetic procedures has surged in recent years. The American Society of Plastic Surgeons reported more than 1.5 million cosmetic procedures performed in 2023 in the United States, with injectables like Botox and dermal fillers topping the charts. Unfortunately, this growth has attracted unscrupulous individuals and businesses eager to exploit consumers’ desires for profit.

Legal 36

Legal Injections Safety Ethics 36

The Dermatology Digest

JANUARY 10, 2025

CAGE Bio, Inc. is initiating a Phase 2b dose-ranging trial for its CGB-500 (1% tofacitinib), a topical Janus kinase (JAK) inhibitor ointment for moderate to severe atopic dermatitis (AD) and low body surface area (BSA) involvement. CGB-500 was developed using CAGE Bio’s proprietary ionic liquid technology. CGB-500 delivers medicine directly through the skin, with minimal systemic exposure.

Dermatitis 36

Dermatitis Safety Technology Dermatology 36

Dermatology Times

JANUARY 10, 2025

At the inaugural Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, reviewed complex cases on AD and PsO and the role of PAs and NPs in advancing patient care.

Dermatology 36

Dermatology 36

The Dermatology Digest

JANUARY 10, 2025

Hoth Therapeutics, Inc.s HT-001 showed promising interim safety and efficacy results from its Phase 2a clinical trial addressing skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. HT-001 topical gel isanticipated to inhibit recruitment and activation of immune cells, reducing inflammation. Fully 100% of patients in Cohort 1 achieved the primary efficacy endpoint of an Acneiform Rash Investigator Global Assessment Scale (ARIGA) score 1, showing signi

Treatments 36

Treatments Safety Clinic Dermatology 36

Dermatology Times

JANUARY 10, 2025

A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.

Treatments 36

Treatments 36

Dermatology Times

JANUARY 10, 2025

Chronic hand eczema poses diagnostic and treatment challenges due to its multifaceted etiology. New therapies like JAK inhibitors offer hope.

Eczema 36

Eczema Therapy Treatments 36

Dermatology Times

JANUARY 10, 2025

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Innovations 28

Innovations Dermatology Treatments 28

Dermatology Times

JANUARY 10, 2025

93.4% of patients saw a positive change in the appearance of forehead wrinkles after 8 weeks of use.

Wrinkles 28

Wrinkles 28

Dermatology Times

JANUARY 10, 2025

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

Treatments 28

Treatments 28

Dermatology Times

JANUARY 10, 2025

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

Dermatitis 28

Dermatitis 28

Dermatology Times

JANUARY 10, 2025

Patients saw an average clearance rate of 74.46% after just 1 session of laser therapy.

Therapy 28

Therapy 28